Based on the genomic, transcriptomic, proteomic, and clinical cancer database in non-small cell lung cancer and lung adenocarcinoma, individuals with TP53 mutations or TP53 mutation-associated epithelial-mesenchymal transition (EMT) phenotype exhibit elevated PD-L1 mRNA expression and diminished miR-34/miR-200 [31, 43–46]. This evidence concerns the gene TP53 and cancer.